BiotechTube

Romiplostim

Phase 2/3Completed
0 watching 0 views this weekπŸ“ˆ Rising
65
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia

Trial Timeline

Dec 3, 2019 β†’ Oct 29, 2021

NCT ID
NCT04095936

About Romiplostim

Romiplostim is a phase 2/3 stage product being developed by Kyowa Kirin for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04095936. Target conditions include Aplastic Anemia.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (4)

NCT IDPhaseStatus
NCT04095936Phase 2/3Completed
NCT03957694Phase 2/3Completed
NCT02773290Phase 2/3Completed
NCT02868060Phase 1/2Completed

Competing Products

20 competing products in Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
AlefaceptAstellas PharmaPhase 1
33
RomiplostimKyowa KirinPhase 2/3
65
Lenvatinib 24 mgEisaiPhase 2
52
RomiplostimKyowa KirinPhase 2/3
65
AMG531Kyowa KirinPhase 2
52
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
52
Hetrombopag Olamine TabletοΌ›Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
41
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
77
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
PosaconazoleMerckPhase 2
52
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
41
LDK378 + AUY922NovartisPhase 1
33

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85